Print

Purpose

The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • At least 18 years old - Predominantly dry cough for at least 8 weeks - Evaluated and treated by at least one physician for cough - Obtained a chest X-ray or chest CT scan specifically related to the cough with unremarkable results - Access to a computer or tablet that includes a camera and able to use the device independently - Reliable internet access - Willing to agree to maintain confidentiality of personal information (including names) related to others in the study

Exclusion Criteria

  • Under age 18 - Coughing up blood - Current smoker of any substance - History of smoking or 10 or more years - Diagnosed with a chronic lung condition (e.g., COPD, emphysema, lung cancer, idiopathic pulmonary fibrosis, chronic bronchitis, asthma)? (NOTE: If a patient has been told their cough may be (or is likely) due to asthma but they have not had any formal lung testing and asthma treatments have not helped your cough, we don't consider this a formal asthma diagnosis and will not exclude them from the study.) - Diagnosed currently or in the past with head and neck cancer (i.e., cancer of the mouth, nose, or throat). - Complaints of swallowing difficulty - Taking any of the following medications, which have a known side effect of cough: Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik) - Prior BCST treatment with an SLP or respiratory therapist

Study Design

Phase
Early Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Group Telehealth Behavioral Cough Suppression Therapy
  • Behavioral: Behavioral Treatment
    Behavioral cough suppression therapy delivered in a group setting via telehealth.

Recruiting Locations

University of Montana
Missoula, Montana 59812
Contact:
Jane E Reynolds, PhD
406-243-2138
jane.reynolds@mso.umt.edu

More Details

Status
Recruiting
Sponsor
University of Montana

Study Contact

Jane E Reynolds, PhD
406-243-2138
jane.reynolds@mso.umt.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.